Strategic IP approach paves way for growth of leading antibody-based pharma SME


We have been working with Alligator Bioscience AB, a Swedish SME specialising in the development of antibody-based therapeutics for cancer treatment since the company’s formation in 2001. We now actively manage Alligator’s entire patent portfolio, ensuring their IP approach is aligned to their long-term commercial goals and immediate business development priorities.

Our work covers a diverse range of associated activities, including complex drafting and prosecution of patents, freedom-to-operate searches, patent strategy and supporting due diligence activities - especially in relation to partner and licensing agreements, which are essential to the company’s development and growth.

For example, in 2019, we advised on Alligator’s significant, multi-million-dollar license agreement with Chinese biotech company, Biotheus Inc. Following the agreement, which saw a significant uplift in Alligator’s share price, Per Norlén, chief executive of Alligator Bioscience, said:

This agreement is a great recognition of our antibody library and our proven expertise in generating high affinity antibodies against TNFR family members, and this collaboration with an up and coming Chinese biotech firm like Biotheus gives us an entrance to the fast advancing life science market in China."


Through regular client communication and holistic portfolio management, we have been able to develop and manage a comprehensive, diverse and thorough patent portfolio for the company, which reflects its ambitions to bring breakthrough treatments to market through effective collaboration with global partners.